Comments
Loading...
Zymeworks Analyst Ratings and Price Targets | NASDAQ:ZYME | Benzinga
Zymeworks Inc has a consensus price target of $16.62 based on the ratings of 13 analysts. The high is $30 issued by LifeSci Capital on March 11, 2025. The low is $9 issued by Barclays on December 22, 2022. The 3 most-recent analyst ratings were released by LifeSci Capital, HC Wainwright & Co., and Citigroup on March 11, 2025, March 10, 2025, and March 7, 2025, respectively. With an average price target of $20.67 between LifeSci Capital, HC Wainwright & Co., and Citigroup, there's an implied 62.16% upside for Zymeworks Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
LifeSci Capital
HC Wainwright & Co.
Citigroup
Wells Fargo
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Zymeworks
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/11/2025 | Buy Now | 135.39% | LifeSci Capital | — | → $30 | Initiates | → Outperform | Get Alert |
| 03/10/2025 | Buy Now | 2% | HC Wainwright & Co. | Robert Burns43% | $12 → $13 | Maintains | Neutral | Get Alert |
| 03/07/2025 | Buy Now | 49.08% | Citigroup | Yigal Nochomovitz57% | $18 → $19 | Maintains | Buy | Get Alert |
| 12/19/2024 | Buy Now | 9.85% | Wells Fargo | Derek Archila59% | $12 → $14 | Maintains | Equal-Weight | Get Alert |
| 12/16/2024 | Buy Now | 41.23% | JP Morgan | Brian Cheng38% | → $18 | Upgrade | Neutral → Overweight | Get Alert |
| 11/22/2024 | Buy Now | -5.85% | HC Wainwright & Co. | Robert Burns43% | $12 → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 11/07/2024 | Buy Now | 96.16% | Leerink Partners | Andrew Berens49% | $10 → $25 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/04/2024 | Buy Now | 41.23% | Citigroup | Yigal Nochomovitz57% | $16 → $18 | Maintains | Buy | Get Alert |
| 11/01/2024 | Buy Now | -5.85% | HC Wainwright & Co. | Robert Burns43% | $12 → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 11/01/2024 | Buy Now | -5.85% | Wells Fargo | Derek Archila59% | $12 → $12 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 10/28/2024 | Buy Now | 119.69% | Stifel | Stephen Willey51% | $21 → $28 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | -5.85% | HC Wainwright & Co. | Robert Burns43% | $12 → $12 | Reiterates | Neutral → Neutral | Get Alert |
| 09/25/2024 | Buy Now | -5.85% | HC Wainwright & Co. | Robert Burns43% | $10 → $12 | Maintains | Neutral | Get Alert |
| 09/18/2024 | Buy Now | -21.54% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Neutral → Neutral | Get Alert |
| 08/02/2024 | Buy Now | 64.77% | Stifel | Stephen Willey51% | $20 → $21 | Maintains | Buy | Get Alert |
| 06/06/2024 | Buy Now | -21.54% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Neutral → Neutral | Get Alert |
| 05/07/2024 | Buy Now | -21.54% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Neutral → Neutral | Get Alert |
| 05/03/2024 | Buy Now | 25.54% | Citigroup | Yigal Nochomovitz57% | $17 → $16 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -5.85% | Wells Fargo | Derek Archila59% | $14 → $12 | Maintains | Overweight | Get Alert |
| 03/12/2024 | Buy Now | 9.85% | Wells Fargo | Derek Archila59% | $12 → $14 | Maintains | Overweight | Get Alert |
| 03/11/2024 | Buy Now | -21.54% | HC Wainwright & Co. | Robert Burns43% | $8 → $10 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | → $8 | Reiterates | Neutral → Neutral | Get Alert |
| 06/06/2023 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | → $8 | Reiterates | Neutral → Neutral | Get Alert |
| 05/18/2023 | Buy Now | 41.23% | Citigroup | Yigal Nochomovitz57% | $17 → $18 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 49.08% | Stifel | Stephen Willey51% | $18 → $19 | Maintains | Buy | Get Alert |
| 03/31/2023 | Buy Now | -29.38% | JP Morgan | Brian Cheng38% | $8 → $9 | Maintains | Neutral | Get Alert |
| 03/21/2023 | Buy Now | -5.85% | Wells Fargo | Derek Archila59% | → $12 | Assumes | → Overweight | Get Alert |
| 03/21/2023 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | → $8 | Reiterates | → Neutral | Get Alert |
| 03/10/2023 | Buy Now | 33.39% | Citigroup | Yigal Nochomovitz57% | $21 → $17 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | 25.54% | Guggenheim | Charles Zhou34% | → $16 | Reiterates | → Buy | Get Alert |
| 01/24/2023 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | → $8 | Reiterates | → Neutral | Get Alert |
| 01/20/2023 | Buy Now | -21.54% | SVB Leerink | Andrew Berens49% | $8 → $10 | Maintains | Market Perform | Get Alert |
| 01/04/2023 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | $10 → $8 | Maintains | Neutral | Get Alert |
| 12/22/2022 | Buy Now | -29.38% | Barclays | Gena Wang50% | $7 → $9 | Maintains | Equal-Weight | Get Alert |
| 12/20/2022 | Buy Now | -13.69% | Jefferies | Akash Tewari44% | $7.7 → $11 | Upgrade | Hold → Buy | Get Alert |
| 11/21/2022 | Buy Now | -21.54% | HC Wainwright & Co. | Robert Burns43% | $8 → $10 | Maintains | Neutral | Get Alert |
| 11/01/2022 | Buy Now | -37.23% | HC Wainwright & Co. | Robert Burns43% | $40 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 10/24/2022 | Buy Now | 41.23% | Stifel | Stephen Willey51% | $21 → $18 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | -37.23% | SVB Leerink | Andrew Berens49% | $19 → $8 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/04/2022 | Buy Now | -29.38% | Wells Fargo | Nick Abbott19% | $45 → $9 | Assumes | → Overweight | Get Alert |
| 09/14/2022 | Buy Now | 64.77% | Citigroup | Yigal Nochomovitz57% | $27 → $21 | Maintains | Buy | Get Alert |
| 08/26/2022 | Buy Now | 111.85% | Citigroup | Yigal Nochomovitz57% | $28 → $27 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | 49.08% | SVB Leerink | Andrew Berens49% | $18 → $19 | Maintains | Outperform | Get Alert |
| 05/23/2022 | Buy Now | 213.85% | HC Wainwright & Co. | Robert Burns43% | $44 → $40 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 119.69% | Citigroup | Yigal Nochomovitz57% | $30 → $28 | Maintains | Buy | Get Alert |
| 05/09/2022 | Buy Now | 119.69% | Citigroup | Yigal Nochomovitz57% | $30 → $28 | Maintains | Buy | Get Alert |
| 05/05/2022 | Buy Now | 9.85% | Guggenheim | Charles Zhu60% | → $14 | Upgrade | Neutral → Buy | Get Alert |
FAQ
What is the target price for Zymeworks (ZYME) stock?
The latest price target for Zymeworks (NASDAQ:ZYME) was reported by LifeSci Capital on March 11, 2025. The analyst firm set a price target for $30.00 expecting ZYME to rise to within 12 months (a possible 135.39% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zymeworks (ZYME)?
The latest analyst rating for Zymeworks (NASDAQ:ZYME) was provided by LifeSci Capital, and Zymeworks initiated their outperform rating.
When was the last upgrade for Zymeworks (ZYME)?
The last upgrade for Zymeworks Inc happened on December 16, 2024 when JP Morgan raised their price target to $18. JP Morgan previously had a neutral for Zymeworks Inc.
When was the last downgrade for Zymeworks (ZYME)?
The last downgrade for Zymeworks Inc happened on November 1, 2024 when Wells Fargo changed their price target from $12 to $12 for Zymeworks Inc.
When is the next analyst rating going to be posted or updated for Zymeworks (ZYME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zymeworks, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zymeworks was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.
Is the Analyst Rating Zymeworks (ZYME) correct?
While ratings are subjective and will change, the latest Zymeworks (ZYME) rating was a initiated with a price target of $0.00 to $30.00. The current price Zymeworks (ZYME) is trading at is $12.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
